Straits Times Index
3,078.27 +1.11 (+0.04%) Nikkei
33,445.90 +670.08 (+2.04%) Hang Seng
16,440.37 +112.51 (+0.69%) FTSE 100
7,489.84 -23.12 (-0.31%) Bitcoin USD
43,608.69 +2,088.14 (+5.03%) CMC Crypto 200
891.78 +31.23 (+3.63%)
GSK plc (GSK.L)
| Previous close | 1,455.40 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 7,709,426 |
| Market cap | 59.24B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 9.73 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.56 (3.85%) |
| Ex-dividend date | 16 Nov 2023 |
| 1y target est | N/A |
- Business Wire
GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative
PHILADELPHIA, November 13, 2023--GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative
- GlobeNewswire
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe database for novel drug target discovery and other researchSOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”) today announced a new, non-exclusive data license with GSK plc (LSE/NYSE: GSK) which extends their collaboration and enables GSK to c
- GlobeNewswire
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
--101 symptomatic FTD-GRN participants enrolled in INFRONT-3 -- SOUTH SAN FRANCISCO, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has achieved target enrollment in INFRONT-3, the pivotal Phase 3 clinical trial of latozinemab (AL001). INFRONT-3 is evaluating the safety and efficacy of latozinemab in slowing disease progression in individuals with frontotemporal dementia due to a
